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Obesity is associated with a chronic, low-grade,
systemic inflammation that may contribute to the
development of insulin resistance and type 2 dia-
betes. Resveratrol, a natural compound with anti-
inflammatory properties, is shown to improve
glucose tolerance and insulin sensitivity in obese
mice and humans. Here, we tested the effect of a
2-year resveratrol administration on proinflamma-
tory profile and insulin resistance caused by a
high-fat, high-sugar (HFS) diet in white adipose
tissue (WAT) from rhesus monkeys. Resveratrol
supplementation (80 and 480 mg/day for the first
and second year, respectively) decreased adipo-
cyte size, increased sirtuin 1 expression, decreased
NF-kB activation, and improved insulin sensitivity in
visceral, but not subcutaneous, WAT from HFS-fed
animals. These effects were reproduced in 3T3-L1
adipocytes cultured in media supplemented with
serum from monkeys fed HFS ± resveratrol diets.
In conclusion, chronic administration of resveratrol
exerts beneficial metabolic and inflammatory adap-
tations in visceral WAT from diet-induced obese
monkeys.CellINTRODUCTIONOver two-thirds of US adults are overweight or obese, a con-
dition that is assumed to be produced by excess nutrient
intake and possibly by lack of exercise. Obesity is associated
with insulin resistance and an increased risk for type 2 diabetes
(Olefsky and Glass, 2010). Moreover, it is now well established
that excess white adipose tissue (WAT) is related with a state
of chronic, low-grade, systemic inflammation that induces and
sustains insulin resistance (Xu et al., 2003). Activation of the
NF-kB pathway has been shown to directly increase proinflam-
matory cytokine and chemokine gene expression (Suganami
et al., 2007). NF-kB is amajor proinflammatory nuclear transcrip-
tion factor that is sequestered in the cytoplasm in its inactive
state in a complex with members of the inhibitor of kappa B
(IkB) family of inhibitor proteins. Following cell activation, IkB
kinase b (IKK-b) phosphorylates IkB, which causes its ubiquiti-
nation and proteolytic degradation. This, in turn, frees NF-kB
and enables its translocation to the nucleus, where it activates
the transcription of target genes. Hence, pharmacological inhi-
bition of the NF-kB signaling pathway in adipose tissue may
reduce chronic, low-grade, systemic inflammation and confer
protection against insulin resistance and the development and
progression of type 2 diabetes.
Resveratrol, a product of red grapes and nuts, has been
shown to inhibit NF-kB activation and expression of inflamma-
tory genes (Heynekamp et al., 2006), thereby improving glucoseMetabolism 18, 533–545, October 1, 2013 ª2013 Elsevier Inc. 533
Table 1. Monkey Characteristics after Dietary Intervention
SDb HFS Diet HFS + Resv Diet p Value
n 24 10 10
Waist (cm) 41.06 ± 2.03* 55.95 ± 5.93 53.05 ± 3.28 <0.001
Hips (cm) 39.07 ± 1.31* 50.16 ± 3.20 48.60 ± 1.83 <0.001
Total cholesterol (mg/dl) 141.87 ± 6.01 162.40 ± 19.48 159.30 ± 12.18 0.103
LDL-C (mg/dl) 57.54 ± 12.55# 84.20 ± 13.84 73.00 ± 6.59 0.008
HDL-C (mg/dl) 71.67 ± 4.31 58.60 ± 7.80 63.90 ± 7.57 0.037
NEFA (mEq/l) 0.83 ± 0.08 0.64 ± 0.06 0.54 ± 0.06 0.068
Values are presented as mean ± SEM. The data were analyzed using using a linear mixed-effects model (*p < 0.05 SDb versus HFS ± Resv diet; #p =
0.011 SDb versus HFS diet). Hips: n = 24 (SDb); n = 9 (HFS diet); n = 10 (HFS + Resv diet). SDb, standard diet baseline; HFS, high-fat, high-sugar; Resv,
resveratrol; mEq/l, milliequivalent per liter. Blood samples were obtained from fasting animals. See also Table S1 and Figure S2.
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Resveratrol Reduces Adipose Insulin Resistancetolerance and insulin sensitivity in mice (Baur et al., 2006). The
biological effects of resveratrol in mammals are largely attributed
to its ability to activate sirtuin 1 (SIRT1) (Howitz et al., 2003),
a NAD+-dependent deacetylase that regulates a wide range of
biological processes, such as gene silencing, aging, cellular
differentiation, and metabolism (Blander and Guarente, 2004).
However, it was recently shown that resveratrol might not acti-
vate SIRT1 directly, but rather exert its effects on SIRT1 through
inhibition of cyclic AMP (cAMP)-degrading phosphodiesterases
(Park et al., 2012), even though direct SIRT1 activation is not
completely excluded (Dai et al., 2010). Regardless of the mode
of activation, SIRT1-mediated deacetylation of p65 subunit
(RelA) of NF-kB at lysine 310 contributes to the downregulation
of NF-kB transcriptional activity and leads to decreased inflam-
matory response (Yeung et al., 2004) and improved insulin sensi-
tivity in adipocytes and macrophages (Yoshizaki et al., 2009;
2010).
A number of recent studies have determined that short-term
resveratrol supplementation (4–6 weeks) decreases inflamma-
tion (Ghanim et al., 2010; Timmers et al., 2011) and improves in-
sulin sensitivity and metabolic function in adults who are obese
or have type 2 diabetes or in older individuals with impaired
glucose tolerance (Timmers et al., 2011; Crandall et al., 2012;
Brasnyo´ et al., 2011). In contrast, no improvement in metabolic
profile was noted after a 12-week resveratrol supplementation
in nonobese women with normal glucose tolerance (Yoshino
et al., 2012), while promising effects on glucose tolerance have
been reported in primates chronically fed a standard diet sup-
plemented with resveratrol (Marchal et al., 2012). Data from
our laboratory have also shown beneficial effects of long-term
resveratrol administration in nonhuman primates fed a high-fat,
high-sugar (HFS) diet, a diet formulated to encourage obesity
aswell as chronic low-grade inflammation and insulin resistance.
Specifically, resveratrol prevented b cell dedifferentiation in
pancreas (Fiori et al., 2013) and conferred protection against
HFS-induced inflammation of the aortic wall from rhesus mon-
keys fed HFS diet (J.A.M., M. Wang, M.B., J. Zhang, S.-S.
Park, S. Maudsley, S.S. An, L. Santhanam, B. Martin, S. Faulk-
ner, C.H.M., J.A.B., L. Peshkin, D. Sosnowska, A. Csiszar,
Z Ungvari, R.L.H., E.M.T., K.J.P., E.G. Lakatta, R.d.C., unpub-
lished data). Despite these advances, there are no studies
showing the effectiveness of chronic administration of resvera-
trol for improving insulin sensitivity, and HFS diet-induced
alteration in metabolic and inflammatory profiles in WAT from a534 Cell Metabolism 18, 533–545, October 1, 2013 ª2013 Elsevier Innonhuman primate model. The aim of the present study was to
establish the effect of a 2-year resveratrol supplementation on
the proinflammatory profile and insulin resistance caused by
HFS diet in subcutaneous and visceral WAT from rhesus
monkeys, a species close to human.
RESULTS
Rhesus Monkey Characteristics
Table S1 (available online) shows the characteristics preinter-
vention (baseline) of 24 rhesus monkeys included in this study.
The monkeys assigned to diets did not differ in age, weight,
waist, hip, lipids, or glucose metabolism parameters. Postinter-
vention, previous data (Fiori et al., 2013) have proven no meta-
bolic dysregulation at 24 months of dietary interventions, based
on fasting insulin and glucose levels. However, an increase in
insulin area under the curve (AUC) from intravenous glucose
tolerance test (IVGTT) and a decrease in insulin sensitivity index
(ISI) was shown with the HFS ± resveratrol (Resv) diets
compared to baseline, consistent with a weight gain and insulin
resistance (Fiori et al., 2013). In the present study, an additional
analysis was carried out in order to determine the resveratrol
effects at a systemic level after 24months of dietary intervention.
Since the animals in the preintervention state were fed with
a standard diet (SD), and nonsignificant differences were
observed between monkeys fed with SD at baseline (SDb) and
postintervention, we considered the baseline measurements
for the experimental animals to represent the control state (Table
1). Postintervention, HFS ± Resv diets increased the waist and
hip measurements (p < 0.05) when compared with SDb control
group. An increase in low-density lipoprotein (LDL) plasma
levels, a characteristic associated with insulin resistance, was
observed in monkeys fed HFS diet (p = 0.011), with respect to
animals in the SDb control group.
Changes in Gene Expression of Subcutaneous
and Visceral WAT by Resveratrol
To examine possible effects of Resv in adipose tissue, we per-
formed a genome-wide microarray analysis on subcutaneous
WAT from rhesus monkeys at the start of the experiment
(SDb) and after a 2-year treatment with HFS ± Resv diet
(Figure 1). Analysis of the transcript profile revealed that a
significant proportion of the genes whose expression was
modified by HFS were shifted in the opposite direction inc.
Figure 1. Resveratrol Supplementation Induces Changes in Gene
Expression in Two Fat Depots
(A) Gene expression profile from subcutaneous fat of rhesus monkeys fed for 2
years with a high-fat, high-sugar diet (HFS) without or with resveratrol (Resv)
supplementation compared to standard diet-fed animals at baseline (SDb).
(B) Heatmap of immune-related GO terms in subcutaneous fat depot. The
Z score of a given GO term showed a striking difference when comparing
Resv to HFS (Resv_HFS) versus HFS to SDb (HFS_SDb).
(C) Gene expression profile from visceral fat of rhesus monkeys fed for 2 years
with HFS diet ± Resv supplementation compared to SD-fed animals.
(D) Venn diagram of overlapping genes significantly changed in the compari-
son HFS_SD, Resv_HFS, and Resv_SD.
(E) Scatter plot of gene expression values in Resv_HFS versus HSF_SD within
the stress_pathway gene set.
For SDb, n = 24; SD, n = 2; HFS diet, n = 4; and HFS + Resv diet, n = 4. See also
Tables S2 and S3.
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Resveratrol Reduces Adipose Insulin Resistanceresponse to Resv supplementation (Figure 1A). Further analysis
showed a highly related gene signature when comparing the
Z score of a given gene from Resv to either HFS (Resv_HFS)
or SDb (Resv_SDb) (Figure 1A). PAGE was then used to high-Celllight functional pathways most affected by the various dietary
regimens. Focusing in gene categories related to immune
responses and inflammation (i.e., inflammatory response,
tumor necrosis factor receptor activity, chemokine activity,
and others), the Z score of a given gene ontology (GO) term
showed striking differences when comparing Resv to HFS
(Resv_HFS) versus HFS to SDb (HFS_SDb) (Figure 1B). Ingenu-
ity pathway analysis revealed diet-induced alterations in in-
flammation-related biological functions in subcutaneous WAT
(Table S2).
The fact that our animal research protocol did not allow for
the collection of visceral WAT at the onset of the experiment
has prevented us from comparing the effect of HFS ± Resv
diet versus SDb in this fat depot. Nevertheless, visceral
WAT from the 2-year SD group was collected and used for
subsequent comparisons. Consistent with the results obtained
in subcutaneous fat, Resv supplementation elicited a genome-
wide expression profiling that was the opposite of that
observed with HFS feeding (Figure 1C). A clear overlap be-
tween the genes whose expression was significantly altered
by Resv supplementation compared to either SD (Resv_SD)
or HFS (Resv_HFS) is shown in the Venn diagram (Figure 1D).
Using PAGE analysis, we focused on select gene sets known
for their susceptibility to Resv (e.g., electron_transport_chain,
proteasome, aged_rhesus_up, tollpathway, and others), and
found a number of gene sets that were regulated in opposite
directions by HFS_SD versus Resv_HFS in visceral WAT
(Table S3). Indeed, a scatter plot of gene expression values
in HSF_SD within the stress_pathway gene set showed strik-
ingly opposite changes as compared to Resv_HFS (Figure 1E).
Moreover, the transcriptional effect of HFS feeding appears to
have an intrinsic fat depot-specific difference in the regulation
of some gene sets, including proteasome and aged_rhesus_up
(Table S3). These data indicate that HFS feeding ± Resv
supplementation elicits a set of transcriptional changes that is
likely to shape the distinct depot-specific responses in rhesus
monkeys.
Resveratrol Increases the Number of Small Adipocytes
in Visceral WAT
Hematoxylin and eosin staining (H&E) of WAT showed nonsignif-
icant differences in the mean size of adipocytes and adipocyte
frequency distribution when subcutaneous WAT from monkeys
assigned to HFS diet was compared to that of the HFS + Resv
diet group (Figure 2A). However, the analysis of adipocyte fre-
quency distribution in visceral WAT showed a distribution
change toward smaller adipocytes in the HFS + Resv diet-fed
monkeys compared with the HFS diet-fed group. As a result, a
significant difference in the mean size of adipocytes between
both groups was observed (p = 0.032) (Figure 2B).
Increased SIRT1 Protein Levels in Visceral WAT
by Resveratrol Supplementation
SIRT1 protein expression was measured in visceral and subcu-
taneous WAT after dietary intervention (Figure 2). No change in
SIRT1 protein levels was found in subcutaneous fat between
the groups (Figure 2C). However, HFS + Resv diet induced a
significant increase of SIRT1 protein levels in visceral fat when
compared to HFS diet (p = 0.010) (Figure 2D).Metabolism 18, 533–545, October 1, 2013 ª2013 Elsevier Inc. 535
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Figure 2. Resveratrol Decreases Mean Adipocyte Size and Increases SIRT1 Protein Expression in Visceral WAT of Rhesus Monkeys
Maintained on HFS Diet for 2 Years
(A and B) Morphologic characteristics of subcutaneous WAT (A) and visceral WAT (B). H&E sections of WAT from monkeys fed HFS and HFS + Resv diet are
shown. Images were captured at 203 magnification. Scale bar = 200 mm. Mean adipocyte size and adipocyte frequency distribution show cell surface areas in
both fat depots after 24 months of dietary intervention. In (A), n = 7 (HFS diet); n = 8 (HFS + Resv diet). In (B), n = 8 for each group.
(C and D) SIRT1 protein levels in subcutaneous WAT (C) and visceral WAT (D). n = 10 for each group.
Results are expressed in a dot plot format, representing the individual data and the mean. The data were analyzed using independent samples t test to analyze
statistical significance between HFS versus HFS + Resv diet at 24 months of dietary intervention. *p < 0.05 (HFS versus HFS + Resv diet). HFS, high-fat,
high-sugar; Resv, resveratrol; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue. See also Figure S3.
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Resveratrol Reduces Adipose Insulin ResistanceResveratrol Inhibits NF-kB Activation and Expression
of Target Genes in Visceral WAT
A decrease in NF-kB activation, as evidenced by a substantial
increase of IkBa protein levels (p = 0.003) (Figure 3A), and a
reduction of NF-kB phosphorylation (p = 0.02) (Figure 3B)
and acetylation (p = 0.05) (Figure 3C) was found in visceral
fat of rhesus monkeys fed with HFS + Resv diet as compared
with HFS diet. Inhibition of the NF-kB signaling by Resv was
accompanied by a decrease of NF-kB target gene expression
(interleukin 6 [IL-6], p = 0.05; IL-1b, p = 0.048) (Figure 3D).
However, regulation of NF-kB in the subcutaneous adipose
tissue was refractory to Resv supplementation (Figures 3E
and 3F).536 Cell Metabolism 18, 533–545, October 1, 2013 ª2013 Elsevier InTo extend the results obtained in visceral fat, we next quanti-
fied the circulating levels of several inflammatory pathway
components and found the concentration of proinflammatory
IL-1b to be significantly higher after consumption of a HFS ±
Resv diet compared to SDb control (p < 0.05) (Table S4). Non-
significant differences between groups were observed in
the other variables analyzed (IL-6, C-reactive protein [CRP],
TNF-a, and adiponectin) (Table S4).
Resveratrol Modulates the Expression of Insulin-
Signaling Protein Markers in Visceral WAT
An increase of insulin receptor substrate 1 (IRS-1) protein
levels (p = 0.05) (Figure 4A), a decrease of Akt serine 473c.
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Figure 3. Resveratrol Decreases Inflammatory Response in Visceral WAT of Rhesus Monkeys Fed a HFS Diet for 2 Years
(A) IkBa protein levels in visceral WAT. n = 10 for each group.
(B) Phosphorylated NF-kB/NF-kB ratio in visceral WAT. n = 9 (HFS diet); n = 8 (HFS + Resv diet).
(C) Acetylated NF-kB protein content in visceral WAT. IP with a control immunoglobulin G (IgG) did not result in NF-kB detection (data not shown). n = 10 (HFS
diet); n = 9 (HFS + Resv diet).
(D) mRNA expression for IL-6, TNF-a, IL-1b, and adiponectin in visceral WAT. For IL-6 and IL-1b, n = 8 (HFS diet); n = 10 (HFS + Resv diet). For TNF-a and
adiponectin, n = 7 (HFS diet); n = 10 (HFS + Resv diet).
(E) IkBa protein levels in subcutaneous WAT. n = 10 for each group.
(F) Phosphorylated NF-kB/NF-kB ratio in subcutaneous WAT. n = 9 (HFS diet); n = 10 (HFS + Resv diet).
Results are expressed in a dot plot format, representing the individual data and the mean. The data were analyzed using independent samples t test to analyze
statistical significance between HFS versus HFS + Resv diet at 24 months of dietary intervention. IL-1b gene expression was log-transformed before statistical
analysis. *p < 0.05 (HFS versus HFS + Resv diet). HFS, high-fat, high-sugar; Resv, resveratrol; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue;
pNF-kB, phosphorylated NF-kB. See also Tables S4 and S5.
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Resveratrol Reduces Adipose Insulin Resistancephosphorylation (p = 0.003) (Figure 4B), and an increase in
the content of insulin-responsive GLUT4 glucose transporter
(p = 0.033) (Figure 4C) were observed in visceral fat depots
from fasted monkeys in the HFS + Resv group as compared to
HFS diet controls. It is important to note that chronic stimulationCellof Akt in adipocytes and transgenic mice overexpressing consti-
tutively active Akt elicits negative feedback on insulin signaling
(Ozes et al., 2001; Nagoshi et al., 2005). Therefore, reduction in
phosphoactive Akt in adipocytes of fasted monkeys maintained
on HFS + Resv diet versus HFS supports the notion of anMetabolism 18, 533–545, October 1, 2013 ª2013 Elsevier Inc. 537
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Figure 4. Resveratrol Improves Insulin Sensitivity in Visceral WAT of Rhesus Monkeys Fed a HFS Diet for 2 Years
(A) IRS-1 protein expression. n = 8 (HFS diet); n = 10 (HFS + Resv diet).
(B) Phosphorylated Akt/Akt ratio. n = 9 (HFS diet); n = 10 (HFS + Resv diet).
(C) GLUT4 protein levels. n = 10 (HFS diet); n = 9 (HFS + Resv diet).
(D) TUG protein content. n = 10 (HFS diet); n = 9 (HFS + Resv diet).
Results are expressed in a dot plot format, representing the individual data and the mean. The data were analyzed using independent samples t test to analyze
statistical significance between HFS versus HFS + Resv diet at 24 months of dietary intervention. *p < 0.05 (HFS versus HFS + Resv diet). HFS, high-fat,
high-sugar; Resv, resveratrol; VAT, visceral adipose tissue; pAkt, phosphorylated Akt. See also Figure S1.
Cell Metabolism
Resveratrol Reduces Adipose Insulin Resistanceimproved insulin sensitivity in visceral WAT from the HFS + Resv
diet-fed animals.
In unstimulated fat and muscle cells, GLUT4 is sequestered
intracellularly in part by binding the Tether, containing a UBX
domain, for GLUT4 (TUG) protein (Bogan et al., 2003). Insulin
stimulates TUG endoproteolytic cleavage to mobilize intracel-
lular GLUT4 storage vesicles to the plasma membrane, an
action that allows glucose to enter the cells by facilitative trans-
port (Bogan et al., 2012). Here, TUG protein levels tended to be
higher in the HFS + Resv group compared to the HFS group,
although these differences did not reach statistical significance
(Figure 4D).
Refractoriness of Visceral WAT Mitochondria to
Resveratrol Treatment
To test if the Resv-mediated expression of classical markers of
insulin signaling pathway was associated to an effect of this538 Cell Metabolism 18, 533–545, October 1, 2013 ª2013 Elsevier Inpolyphenol in visceral WAT mitochondria, we analyzed mito-
chondrial content (citrate synthase activity, mRNA expression
for cytochrome b [CytB], NADH dehydrogenase 1 [ND1], ND2,
ND5, and ND6, and NADH dehydrogenase [ubiquinone] 1 alpha
subcomplex 9 [NDUFA 9] protein levels), mitochondrial biogen-
esis (mRNA expression for PPARg coactivator 1 [PGC-1a] and
dimethyladenosine transferase 2 mitochondrial [TFB2M]), and
oxidative stress (H2O2 and lysine 4-hydroxynonenal [HNE] levels)
in this fat depot from rhesus monkeys after dietary intervention.
Nonsignificant changes between HFS and HFS + Resv diet were
observed in these parameters (Figure S1).
Serum from Resveratrol-Treated Monkeys Elicits
Anti-Inflammatory Effects and Improves Insulin
Signaling in 3T3-L1 Adipocytes
The inflammatory profile of fully differentiated 3T3-L1 adipocytes
was assessed after a 24 hr incubation with media containingc.
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Figure 5. Serum from Resveratrol-Treated Monkeys on HFS Diet Exerts Anti-Inflammatory Effects in 3T3-L1 Adipocytes
(A) SIRT1 protein levels.
(B) IkBa protein levels.
(C) Phosphorylated NF-kB/NF-kB ratio. Lanes were run on the same gel but were noncontiguous.
(D) mRNA expression for IL-6, TNF-a, IL-1b, and adiponectin.
Fully differentiated 3T3-L1 adipocytes were incubated for 24 hr with media containing serum from SD and HFS ± Resv diet-fed monkeys for 2 years. The graphs
show the mean ± SEM from three independent experiments, and the results are expressed as percent increase over the values observed in adipocytes treated
with HFS serum. The data were analyzed using one-way ANOVA. *p < 0.05 (HFS versus HFS + Resv serum); #p < 0.05 (HFS versus SD serum). SD, standard diet;
HFS, high-fat, high-sugar; Resv, resveratrol; pNF-kB, phosphorylated NF-kB.
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Resveratrol Reduces Adipose Insulin Resistanceserum frommonkeys fed with SD, HFS, and HFS + Resv diets for
24 months. The results indicated an increase in SIRT1 protein
level (p < 0.05) (Figure 5A) and a decrease in NF-kB phosphory-
lation (p < 0.05) (Figure 5C) after treatment of 3T3-L1 adipocytes
with serum from animals fed SD or HFS + Resv diet as compared
to HFS serum. Moreover, a decrease in NF-kB target gene
expression (IL-6, p = 0.016) was also observed when 3T3-L1
adipocytes were incubated in media containing HFS + Resv
serum versus HFS serum (Figure 5D). A trend toward lower IL-
6mRNAwas foundwith SD serum versus HFS serum (p = 0.056).
This reduction of the proinflammatory profile by the HFS +
Resv serum may correlate with an improvement in insulin sensi-
tivity. Control experiments showed no difference in IRS-1 protein
levels upon treatment of 3T3-L1 adipocytes with the three
serums at baseline (Figure 6A). However, a significant effect of
time (p = 0.017) and the interaction diet and time (p = 0.041)
in Akt activation was found when 3T3-L1 adipocytes that were
pretreated with monkey serum for 24 hr were stimulated with
insulin for 30 min. Specifically, the duration of insulin-inducedCellAkt phosphorylation was markedly longer when 3T3-L1 adipo-
cytes were pretreated with serum from HFS diet group as
compared to that of SD and HFS + Resv diet (Figure 6B). More-
over, a significant increase in the number of cells expressing
GLUT4 at the plasma membrane (p < 0.05) (Figure 6C) and
greater insulin-induced cell surface GLUT4 labeling (p < 0.05)
(Figure 6D) were observed when 3T3-L1 adipocytes were incu-
bated with SD or HFS + Resv serum as compared to HFS serum.
DISCUSSION
Obesity is recognized as a chronic, low-grade, systemic inflam-
mation, which contributes to the development of insulin resis-
tance (Gustafson et al., 2007). Approaches aimed to reduce
adipose tissue inflammation may be effective at improving
insulin resistance. In this sense, the polyphenol Resv has been
shown to improve glucose tolerance and insulin sensitivity in
diet-induced obese mice (Baur et al., 2006; Lagouge et al.,
2006) and in obese people (Timmers et al., 2011). Here, geneMetabolism 18, 533–545, October 1, 2013 ª2013 Elsevier Inc. 539
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Figure 6. Serum from Resveratrol-Treated
Monkeys on HFS Diet Improves Insulin
Signaling in 3T3-L1 Adipocytes
(A) IRS-1 protein levels in 3T3-L1 adipocytes incu-
bated for 24 hr with media containing serum from
SD and HFS ± Resv diet-fed monkeys for 2 years
(n = 3). Lanes were run on the same gel but were
noncontiguous.
(B) Phosphorylated Akt/Akt ratio in 3T3-L1 adipo-
cytes pretreated for 24 hr with media containing
serum from SD and HFS ± Resv diet-fed monkeys
for 2 years and stimulated with insulin (100 nM) for
10, 20, and 30 min (n = 3).
(C) Number of cells expressing GLUT4 at the
plasma membrane. 3T3-L1 adipocytes were incu-
bated for 24 hr with media containing serum from
SD and HFS ± Resv diet-fed monkeys for 2 years
and then treated in the absence (0 min) or presence
of 100 nM insulin (30 min). GLUT4-labeled sections
of 3T3-L1 adipocytes are shown. Images were
captured at 103 magnification. Scale bar = 90 mm.
The number of cells that were stained for GLUT4
at the plasma membrane over total cell number in
both control and insulin-treated cells were counted
(n = 5).
(D) Insulin-induced cell surface GLUT4 labeling.
3T3-L1 adipocytes were pretreated for 24 hr with
media containing serum from SD and HFS ± Resv
diet-fed monkeys for 2 years and then stimulated
with insulin (100 nM) for 30 min. GLUT4-labeled
sections of 3T3-L1 adipocytes are shown. Images
were captured at 603 magnification. Scale bar =
15 mm. The amount of GLUT4 labeling at the plasma
membrane of insulin-treated cells was normalized
by the total GLUT4 staining in the same cells (n = 5).
For (A–D), the graphs show the mean ± SEM, and
the results are expressed as percent increase
over the values observed in adipocytes treated
with HFS serum (A and D) or as percent increase
over the values observed in adipocytes at baseline
(B and C).
The data were analyzed using One-Way ANOVA,
and RM-ANOVA was used to calculate the time
effect (p time), the diet effect (p diet), and the diet3
time interaction (p diet 3 time). *p < 0.05 (HFS
versus HFS + Resv serum); #p < 0.05 (HFS versus
SD serum). SD, standard diet; HFS, high-fat, high-
sugar; Resv, resveratrol; pAkt, phosphorylated Akt;
PM, plasma membrane.
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Resveratrol Reduces Adipose Insulin Resistanceexpression studies and pathway analyses revealed that Resv
supplementation partly protects adipose tissue from transcrip-
tional changes that lead to activation of proinflammatory and
stress responses in rhesus monkeys upon HFS feeding. Some
of the transcriptional changes induced by a 2-year HFS ± Resv
supplementation were fat depot specific, which may be the
cause of the observed alterations in visceral versus subcutane-
ous WAT after dietary intervention. We show that long-term
Resv supplementation reduced adipocyte size, increased
SIRT1 protein levels, and decreased both NF-kB activation and
several inflammatory markers in visceral WAT of diet-induced
obese rhesus monkeys. Moreover, chronic administration of
Resv elicited an appropriate expression of classical markers
of the insulin signaling pathway in visceral WAT. The fact that540 Cell Metabolism 18, 533–545, October 1, 2013 ª2013 Elsevier Inthese effects were partially reproduced in 3T3-L1 adipocytes
incubated with media supplemented with serum from monkeys
fed HFS ± Resv indicated that adipocytes may contribute
to the development of these metabolic and inflammatory
adaptations.
Resveratrol has received considerable attention for its ability
to activate SIRT1, an enzyme that deacetylates a range of
substrates including PGC-1a, uncoupling protein 2 (UCP-2),
NF-kB, and FoxO1, which in turn results in a profound effect
on glucose homeostasis and insulin secretion in rodents (Rodg-
ers et al., 2005, Kitamura et al., 2005, Moynihan et al., 2005). In
adipose tissue, SIRT1 represses adipocyte differentiation and
expression of genes controlled by PPARg (Picard et al., 2004)
while increasing FoxO1-mediated adiponectin expression inc.
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tive thermogenesis in brown adipose tissues (Puigserver et al.,
1998). Moreover, SIRT1 has been implicated in the negative
regulation of the NF-kB inflammatory response in 3T3-L1 adipo-
cytes (Yoshizaki et al., 2009). Because of the growing evidence
that links chronic low-grade inflammation to the development
of insulin resistance (Cai et al., 2005) and the ability of SIRT1 to
reduce inflammation and improve glucose tolerance in mice
(Ramsey et al., 2008), it was imperative to extend these findings
to a species close to human. Toward this end, we studied the
effect of chronic administration of Resv on the HFS diet-induced
proinflammatory state and insulin resistance in rhesus monkey
WAT and found that significant changes in adipocyte size,
SIRT1 expression, and NF-kB activity were observed in visceral
WAT, but not subcutaneous WAT, indicative of functional differ-
ences among fat depots (Coon et al., 1992; Gastaldelli et al.,
2002). Consequently, the ability of Resv to regulate NF-kB target
gene expression was examined in visceral WAT. A decrease in
IL-6 and IL-1b mRNA levels was observed in the HFS + Resv
group when compared to HFS-fed animals, consistent with
earlier observations showing that Resv reduces proinflammatory
cytokine expression in cultured mouse and human adipocytes
(Gonzales andOrlando, 2008; Kennedy et al., 2009) and in rodent
WAT (Rivera et al., 2009). These findings in our study were asso-
ciated with a reduction in the inflammatory profile of aortic wall
(J.A.M., M. Wang, M.B., J. Zhang, S.-S. Park, S. Maudsley,
S.S. An, L. Santhanam, B. Martin, S. Faulkner, C.H.M., J.A.B.,
L. Peshkin, D. Sosnowska, A. Csiszar, Z. Ungvari, R.L.H.,
E.M.T., K.J.P., E.G. Lakatta, R.d.C., unpublished data) from
monkeys assigned to HFS + Resv diet, without changes in
circulating proinflammatory cytokine levels. This latter result
could be due to a variety of reasons, such as duration of dietary
intervention and/or the effect of Resv in other contributors
of systemic inflammation (e.g., liver and muscle).
Adipose tissue is composed of mature adipocytes and the
stromavascular fraction that contains preadipocytes, blood
cells, and macrophages. IL-1b and IL-6 are produced by adipo-
cytes (Trayhurn and Wood, 2005), and the increase in inflamma-
tory response following SIRT1 depletion in 3T3-L1 adipocytes
is reversed upon cell treatment with SIRT1 activators (Yoshizaki
et al., 2009). In support of the latter study, we observed that 3T3-
L1 adipocytes treated with media supplemented with serum
frommonkeys fed with HFS +Resv diet had higher SIRT1 protein
levels but lower NF-kB phosphorylation and IL-6 mRNA expres-
sion when compared to the HFS-fed animals. Taken together,
these data indicate that adipocytes contribute, at least in part,
to the beneficial effects of Resv in visceral WAT.
Studies conducted in healthy obese men (Timmers et al.,
2011) and patients with type 2 diabetes (Brasnyo´ et al., 2011)
demonstrate that 4-week Resv administration exerts beneficial
effects on systemic insulin sensitivity. However, others per-
formed in subjects with impaired glucose tolerance (Crandall
et al., 2012) and normal-weight healthy individuals (Ghanim
et al, 2010) have shown nonsignificant changes in fasting
glucose or insulin levels after acute resveratrol supplementation
(4–6 weeks). These contradictory results warrant additional
studies on the effect of long-term resveratrol supplementation.
Long-term treatment of adipocytes with IL-6 or IL-1b inhibits
IRS-1 and GLUT4 expression (Rotter et al., 2003; Jager et al.,Cell2007). Likewise, lower IRS-1 and GLUT4 content is observed
in adipocytes from patients with type 2 diabetes (Carvalho
et al., 1999; Garvey et al., 1991) and in insulin-resistant subjects
(Carvalho et al., 1999; Shepherd and Kahn, 1999). Moreover,
there is emerging evidence showing that prolonged activation
of Akt leads to negative feedback of insulin signaling (Ozes
et al., 2001; Nagoshi et al., 2005), possibly through a p65/
RelA-mediated increase in the phosphorylation and expression
of Akt (Meng and D’Mello, 2003). We report that long-term
Resv supplementation improved expression of classical markers
of insulin signaling cascade in visceral adipose tissue of HFS-fed
rhesus monkeys through increased IRS-1 protein levels, lower
chronic activation of Akt, and higher GLUT4 protein content.
This effect in visceral WAT was associated with a preservation
of pancreas morphology without improvement of insulin sensi-
tivity at the systemic levels (Fiori et al., 2013). This latter finding
may be partly explained by the fact that 2-year Resv
supplementation may not be sufficient to observe systemic
changes in glucose homeostasis in rhesus monkeys. In this
sense, Marchal et al. (2012) did not observe differences in insulin
sensitivity and glycemia markers between gray mouse lemurs
fed standard diet and those fedwith standard diet supplemented
with Resv at 21 months of dietary intervention. However,
after 33 months, Resv decreased glycemia after the oral
glucose loading and homeostatic model assessment-insulin
resistance (HOMA-IR) index compared with standard diet in
these nonhuman primates. Finally, although Resv potently
increases mitochondrial function and biogenesis through PGC-
1a in muscle and brown adipose tissue and confers protection
against diet-induced obesity and insulin resistance in mice
(Lagouge et al., 2006), we did not observe an improvement of
mitochondrial content in visceral WAT of HFS + Resv diet-fed
rhesus monkeys, indicating a possible tissue-specific effect of
Resv. In agreement with us, Lagouge et al. (2006) did not
observe changes in mitochondrial biogenesis in the heart,
despite the coexpression of PGC-1a and SIRT1. Likewise, Chabi
et al. (2009) found that liver, and to a lesser extent adipose tissue,
from rats shows high levels of SIRT1 activity, despite having
low PGC-1a protein content, which is in accordance with the
reported role of SIRT1 in the activation of lipolysis and gluco-
neogenesis (Picard et al., 2004; Rodgers et al., 2005) but does
not indicate that the SIRT1 expression pattern is related to the
oxidative capacity of a given tissue. Alternatively, long-lived
species, such as primates and humans, may have a different
bioenergetics response to Resv compared to short-lived
species (e.g., mice and rats).
To demonstrate that Resv effectively improves insulin sensi-
tivity in WAT, we studied the effects of this compound in 3T3-
L1 adipocytes and found that the serum from rhesus monkeys
fed with HFS + Resv diet normalized insulin-induced Akt
activation and increased the number of cells expressing
GLUT4 and the quantity of this glucose transporter at the
plasma membrane in response to an acute insulin challenge.
However, Resv was also found to increase the insulin-stimulated
phosphorylation of Akt in 3T3-L1 adipocytes (Kang et al., 2012).
Differences in experimental conditions (e.g., insulin con-
centration; monkey serum versus inflammatory conditioned
media from lipopolysaccharide-stimulated RAW264.7 cells;
Resv administered to monkeys for 2 years versus Resv additionMetabolism 18, 533–545, October 1, 2013 ª2013 Elsevier Inc. 541
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for the opposite results between the two studies. It is interesting
that Resv reduces serine phosphorylation of IRS-1 and a sub-
sequent degradation of the protein through inhibition of Akt
and JNK activity in insulin-resistant muscle cells (Fro¨jdo¨ et al.,
2011).
In conclusion, our data suggest that before evidence of
dysglycemia is uncovered, the chronic administration of Resv
produces beneficial metabolic and inflammatory adaptations
in visceral WAT of a diet-induced obese nonhuman primate
model. In addition, we demonstrate that adipocytes are partly
responsible for the favorable adaptations produced by Resv in
visceral WAT. Although lifestyle changes and pharmacotherapy
are the primary interventions to improve insulin resistance, they
are difficult to follow and maintain and may be too late, as
changes predisposing patients to diabetes could have already
happened in pancreas and peripheral tissues. Since Resv was
well tolerated at the tested concentrations, long-term Resv
supplementation may provide a safe approach to reduce the
chronic inflammatory properties associated with obesity while
restoring insulin responsiveness in visceral WAT.EXPERIMENTAL PROCEDURES
Animals
Adult (7–13 years old) male rhesusmonkeys (24;Macacamulatta) were housed
at the NIH Animal Center, Poolesville, MD, a center fully accredited by
the American Association for Accreditation of Laboratory Animal Care. All
procedures were approved by the Animal Care and Use Committee of the
NIA Intramural Program. Details of animal care are provided in the Supple-
mental Information.
After a baseline assessment, the animals were subjected to a dose escala-
tion study of 2-year of duration. Monkeys were quasi-randomized into one of
three groups: HFS diet + Resv (n = 10), HFS diet + placebo (n = 10), and stan-
dard diet (SD) (n = 4). The three diets were isoenergetics (52 kcal/kg body
weight per day). The SD was a commercially available closed formula monkey
chow (TestDiet #5038; Purina Mills), with 13% of kcal in fat and 2.24% sucrose
by weight. The main sources of macronutrients in the SD were as follows:
protein (soy meal, corn); fat (porcine fat, corn); carbohydrate (corn, wheat
middlings). The HFS diet was a specially formulated, purified-ingredient diet
with 42% of kcal in fat and approximately 27% sucrose by weight (Custom
formula #07802; Harlan, Teklad). The main sources of macronutrients in the
HFS diet were as follows: protein (casein, lactalbumin); fat (milk fat, soybean
oil); carbohydrate (sucrose and maltodextrin). Macronutrient compositions in
both diets were as follows: (1) SD diet: 18.2% of kcal in protein, 13.1% of
kcal in fat, 68.7% of kcal in carbohydrate, 2.24% sucrose; (2) HFS diet:
15.8% of kcal in protein, 42.3% of kcal in fat, 41.9% of kcal in carbohydrate,
27% sucrose. The monkeys were gradually switched to HFS diet over a
3-week period. Both groups received two meals per day in allotments that
represented ad libitum feeding. Resv (resVida) was supplied by DSM Nutri-
tional Products. Each monkey in the HFS + Resv group received a total daily
dose of 40 mg twice a day. Details of calculation of the dose are provided
in the Supplemental Information. No adverse effects to Resv were evident.
Monkeys in the non-Resv group received a placebo treat. After 1 year, the
Resv dose was increased to 240 mg twice a day to document a dose effect.
Again, no adverse effects were evident. An increase of serum trans-Resv
and its O-sulfated metabolite concentration (p < 0.05) was observed with the
dosage increments (40 versus 240 mg twice daily) in the HFS + Resv group
(Figure S2).
Blood and Adipose Tissue Sample Collection
In monkeys anesthetized with ketamine (7–10 mg/kg, intramuscular), fasting
blood samples were obtained by venipuncture of the femoral vein at 0, 9,
and 24 months of dietary intervention, and subcutaneous adipose tissue542 Cell Metabolism 18, 533–545, October 1, 2013 ª2013 Elsevier Inwas collected via an open incision at the ventral midline of the abdomen at
month 0 of dietary intervention. Adipose tissue was obtained at 24 months
of dietary intervention after the fastingmonkeyswere anesthetizedwith a lethal
dose of sodium pentobarbital (50 mg/kg, intraperitoneal). Once deeply
sedated, the monkeys were perfused with cold lactated Ringer’s solution until
death. A section of subcutaneous adipose tissue was collected via an open
incision at the ventral midline of the abdomen. The peritoneal cavity was
then exposed, and visceral adipose tissue was collected from the omentum.
Samples were stored in cryovials, flash frozen in liquid nitrogen, and stored
at 80C until assayed.
Biochemical Determinations
Total cholesterol, LDL-C, and HDL-C were obtained by a VAP test by Athero-
tech Diagnostics Lab. Serum fasting insulin was determined by ELISA using
a commercially available kit (Mercodia). Fasting glucose was determined
from whole blood with an Ascensia Breeze 2 Blood Glucose Meter (Bayer
HealthCare LLC). Serum trans-Resv and trans-Resv-3-O-sulfate concentra-
tions were measured by a chromatography and mass spectrometry method
as described in the Supplemental Information.
3T3-L1 Cell Culture and In Vitro Experimental Setups
Mouse 3T3-L1 fibroblasts (American Type Culture Collection) were cultured
and differentiated toward adipocytes as previously described (Student et al.,
1980) with modifications. See Supplemental Information for further details.
For treatments, 3T3-L1 adipocytes were cultured with high-glucose Dulbec-
co’s modified Eagle’s medium (DMEM) containing 4 mM glutamine and 1.5 g/l
NaH2CO3 and supplemented with 10% pooled monkey serum from either the
SD, HFS, or HFS + Resv group. After a 24 hr incubation period, cells were
treated with 100 nM insulin for 30 min. 3T3-L1 adipocytes were harvested
for RNA and protein determination and examined for GLUT4 translocation
by immunocytochemistry at the time points indicated in Figures 5 and 6.
Protein Extraction
Adipose tissue (50–100mg) was thawed by adding 250 ml of cold urea/thiourea
buffer (7 M urea [Sigma-Aldrich], 2 M thiourea [Sigma-Aldrich], 4% CHAPS
[USB Affymetrix], 45 mM Tris [pH 7.4; Sigma-Aldrich], 60 mM dithiothreitol
[Sigma-Aldrich], and protease and phosphatase inhibitors [Sigma-Aldrich]).
Cells were mechanically disrupted and briefly sonicated. Samples were incu-
bated for 15 min at 35C and cooled on ice for 10 min. The homogenate was
then centrifuged (15 min, 10,000 3 g, 4C), and the aqueous phase between
the upper lipid phase and lower cellular debris phase was collected. Extensive
delipidation was accomplished by tri-n-butylphosphate, acetone, and meth-
anol (Sigma-Aldrich) precipitation (Gesta et al., 2006). Precipitated proteins
were resuspended in 80 ml of urea/thiourea buffer, and the Lowry assay
method (Bio-Rad) was used to determine protein concentration.
For immunoprecipitation and determination of GLUT4 and TUG protein
content, visceral adipose tissue was mechanically lysed and briefly sonicated
in RIPA buffer supplemented with EDTA and EGTA (Boston BioProducts),
protease and phosphatase inhibitors (Sigma-Aldrich), and 0.1 mM phenylme-
thylsulfonyl fluoride (Sigma-Aldrich). 3T3-L1 adipocytes were also lysed using
the same buffer. The homogenate was then centrifuged, and the aqueous
phase was collected between the upper lipid phase and lower cellular debris
phase. The Bradford assay method (Bio-Rad) was used to determine protein
concentration.
Western Blot and Immunoprecipitation
Protein expression by western blot and acetylated NF-kB quantification by
immunoprecipitation were performed according to standard procedures
as described in the Supplemental Information. Ponceau S staining was
selected as a loading control (Romero-Calvo et al., 2010) because the values
of integrated densitometric peak areas correlated with NF-kB protein levels
when serial dilutions of a visceral WAT protein sample were analyzed (r2 =
0.99; Figure S3).
Gene Expression
Microarray and real-time PCR techniques were carried out according to
standard procedures to determine the effects of Resv on gene expression
of 3T3-L1 adipocytes and WAT from rhesus monkeys. Full methodologicalc.
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sequences used in real-time PCR are summarized in Table S5.
Histology
H&E of paraffin-embedded tissue sections was performed by Histoserv.
Samples were visualized under an optical microscope (DAS Mikroskop Leitz
DMR; Leica Microsystems), and image stacks were analyzed with ImageJ
software. To evaluate mean size and adipocyte frequency distribution, the
surface area of a minimum of 370 cells per group was analyzed.
Immunocytochemistry
3T3-L1 adipocytes were fixed in 4% paraformaldehyde (15 min), incubated
with PBS containing 0.3% Triton X-100 and 1%BSA (1 hr at room temperature
[RT]), and then exposed to rabbit anti-GLUT4 antibody (1:100; Abcam). After
an overnight incubation at 4C, an anti-rabbit Alexa488-conjugated secondary
antibody (1:500; Invitrogen) was added. Samples were visualized under a
DeltaVision high-resolution microscope (Applied Precision). Image stacks
were deconvolved with DeltaVision microscope software and analyzed with
ImageJ software. To evaluate the number of cells expressing GLUT4 at the
plasma membrane, a ratio of the number of cells that were stained for
GLUT4 at the cell surface over the total number of cells was calculated. A min-
imum of 650 cells per group was counted. Moreover, a minimum of 90 cells
positive for cell surface GLUT4 labeling per group was used to quantitatively
assess the effect of insulin on the amount of GLUT4 present at the plasma
membrane over total GLUT4 staining. Negative control samples without the
primary antibody were included to assess nonspecific staining.
Enzyme-Linked Immunosorbent Assay
Plasma or serum concentrations of IL-6, TNF-a, IL-1b, CRP, adiponectin, and
nonesterified fatty acids (NEFA) were determined in duplicate with commer-
cially available ELISA kits: IL-6, TNF-a, and IL-1b (Cell Sciences); adiponectin
(AdipoGen); CRP (Uscn Life Science Inc.); NEFA (Wako Diagnostics).
Citrate Synthase Activity and Hydrogen Peroxide Determination
Visceral adipose tissue was homogenized in RIPA buffer supplemented with
EDTA and EGTA (Boston BioProducts), protease and phosphatase inhibitors
(Sigma-Aldrich), and 0.1 mM phenylmethylsulfonyl fluoride (Sigma-Aldrich).
Citrate synthase was determined by spectrophotometric methods in 20 mg
of protein lysates following the method described by Bernier et al. (2011).
Hydrogen peroxide was determined using an Amplex Red Hydrogen
Peroxide/Peroxidase Assay Kit (Invitrogen).
Data Analysis
In vitro data presented in the text, figures, and tables are expressed as mean ±
SEM. The AUC was determined using GraphPad Prism. Boxplot graphs were
generated using statistical software to detect outliers within each variable. The
repeated-measures data were analyzed using a linear mixed-effects model.
Fisher’s exact test (right-tailed), Z test, independent samples t test, one-way
ANOVA, and repeated-measures ANOVA (RM-ANOVA) were also used, as
appropriate. p < 0.05 was considered statistically significant. Full statistical
analysis details are described in the Supplemental Information.
ACCESSION NUMBERS
Raw microarray data sets have been submitted to the NCBI GEO database
under accession number GSE50005.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and five tables and can be found with this article online at
http://dx.doi.org/10.1016/j.cmet.2013.09.004.
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